<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Friday, November 22, 2019</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| Brain                  | **NRG Oncology RTOG 1205:** Randomized phase II trial of concurrent bevacizumab and re-irradiation vs. bevacizumab alone as treatment for recurrent glioblastoma  
**Presenter:** Christina Tsien  
**Abstract #:** ACTR-32 | 1:30 PM – 5:00 PM  
Concurrent Session 1A-Adult Clinical Trials I/Radiation  
Location: Grand Canyon 1-6  
Time: 2:10 PM – 2:20 PM |
| Brain                  | **NRG/RTOG 9402:** Final results with chemoradiotherapy for anaplastic oligodendroglial tumors from NRG Oncology/RTOG 9402  
**Presenter:** Andrew Lassman  
**Abstract #:** ACTR-13 | 1:30 PM – 5:00 PM  
Concurrent Session 1A-Adult Clinical Trials I/Radiation  
Location: Grand Canyon 1-6  
Time: 2:20 PM – 2:30 PM |
| Brain                  | **NRG-CC001:** Preservation of neurocognitive function & patient-reported symptoms with hippocampal avoidance (HA) during whole-brain radiotherapy (WBRT) for brain metastases: Long-term results of NRG Oncology CC001  
**Presenter:** Terri Armstrong  
**Abstract #:** ACTR-50 | 3:15 PM – 5:00 PM  
Concurrent Session 2A-Adult Clinical Trials II/Immunology Pre-Clinical I  
Location: Grand Canyon 1-6  
Time: 3:15 PM - 3:25 PM |

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Saturday, November 23, 2019</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| Brain                  | **Ongoing Trials:** Update on Ongoing Trials – NRG  
**Presenter:** Leland Rogers | 7:00 AM – 8:30 AM  
Sunrise Session: Clinical Trials in Meningiomas: Updates, Ongoing and New Proposed Trials  
Location: Grand Saguaro North  
Time: 7:00 AM – 7:10 AM |
| Brain                  | **NRG/RTOG 0424:** Neurocognitive function (NCF) and quality of life (QOL) results from a phase II study of temozolomide-based chemoradiotherapy regimen for high risk low-grade gliomas  
**Presenter:** Jeffrey Wefel  
**Abstract #:** NCOG-01 | 11:02 AM – 12:00 PM  
Plenary  
Location: Grand Canyon Salon  
Time: 11:02 AM – 11:12 AM |
| Brain                  | **NRG-BN006:** NRG Oncology NRG-BN006: A phase II/III randomized, open-label study of Toca 511 and Toca FC with standard of care compared to standard of care in patients with newly diagnosed glioblastoma  
**Presenter:** Manmeet Ahluwalia  
**Abstract #:** RBTT-11 | 5:00 PM – 7:00 PM  
Poster Session  
Location: Ballroom Lawn |